Chronic clofibrate therapy in maintenance hemodialysis patients.
21 hypertriglyceridemic hemodialysis patients were treated with 1--2 g/week of clofibrate. The dosage reduction from the usual clofibrate dose of 14 g/week avoided toxicity and corrected the abnormalities in serum triglyceride and high density lipoprotein cholesterol levels to or toward normal.
D000328:Adult; D001161:Arteriosclerosis / Q000150:complications / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications / Q000517:prevention & control; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy*; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D006435:Renal Dialysis
D008055:Lipids; D002784:Cholesterol; D002994:Clofibrate